Primary open-angle glaucoma (POAG) is a progressive optic neuropathy that, left untreated, can lead to irreversible damage to the optic nerve and permanent vision loss. To date, intraocular pressure (IOP) is the only modifiable risk factor for disease progression, and topical eye-drops are currently used as the leading non-surgical glaucoma therapy. Despite the efficacy of pharmacotherapy in lowering IOP, success is ultimately defined by patient compliance and patient persistence. Ocular tolerability is a crucial factor in patient compliance and persistence; non-adherence owing to adverse effects can lead to poor control of IOP and treatment failure. Prostaglandin analogues are currently the first-line antiglaucoma agents, with a good tolerability profile and a better IOP-lowering effect compared with β-blockers.
persistence are significant factors that can affect patient outcome. It is important for physicians to consider these factors when selecting a medical therapy, while also stressing the importance of treatment adherence to their glaucoma patients. Non-adherence due to poor ocular tolerability can lead to treatment failure because of inadequate IOP control. Glaucoma treatment should therefore be determined with regard not only to IOP lowering, but also to minimisation of systemic and ocular adverse events, while taking into account compliance as part of individualisation of patient care.
From β-blockers to Prostaglandin Analogues and Beyond
Generally, initial treatment for lowering IOP is topical medical therapy with monotherapy as first choice. Several classes of antiglaucoma medication are currently available, including β-blockers, prostaglandin analogues, alpha-2 adrenergic agonists, topical carbonic anhydrase inhibitors (CAIs) and parasympathomimetic agonists. The latest European Glaucoma Society guidelines recommend that the choice of initial monotherapy be based on physician preference. 4 In recent years prostaglandin analogues have emerged as first-line agents. Current data show that 40-75% of glaucoma patients fail monotherapy after more than two years of treatment. 10, 16 In these patients, combination therapy and/or further adjunctive therapy is often considered.
β-blockers β-adrenergic antagonists block the β-receptors in the ciliary body, thereby decreasing aqueous humour production. 
Combination Therapy
Although the prostaglandin analogues have a strong IOP-lowering profile, many patients still require a multimodal approach with multiple topical medications in order to achieve target pressure control; 10, 16 patients are commonly treated primarily with a prostaglandin plus an additional drug in combination. 22, [30] [31] [32] In some cases where target IOP is still not achieved, the addition of a third drug may be considered. However, the use of multiple topical treatments increases the risk of adverse effects and nonadherence. The convenience of dosing in these multiple drug regimens can be improved via fixed drug combinations, the most recent addition to the armamentarium of antiglaucoma drugs. The simplicity of a single as opposed to multiple administration has been shown to improve patient adherence. 33 Fixed combinations also prevent medication washout, which occurs when patients on multiple drugs apply their medications with too short an interval between drops, leading to a significant washout effect. 34 Moreover, in the event of needing to add a β-blocker to a prostaglandincontaining regimen, a once-daily fixed-dose combination product would administer less β-blocker than a twice-daily regimen, thereby reducing the rate or severity of adverse effects, as well as the daily topical preservative load, without sacrificing efficacy.
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Several fixed-combination formulations are now available and all contain a β-blocker as one component.
Fixed-combination therapies are now widely used in glaucoma therapy, particularly the combination of the prostaglandin analogue latanoprost and the β-blocker timolol, and that of the CAI dorzolamide and timolol. The fixed combination of latanoprost/ timolol has been extensively studied, and has been shown to be As well as benefits, there are also limitations associated with fixed combinations of antiglaucoma agents, the most obvious of which is the inability to alter the dosing frequency of the components in the combination product. This can potentially hinder the ability to tailor therapy towards the individual, and can interfere with the optimal dosing schedule.
The Importance of Long-term Patient Compliance, Medication Persistence and Ocular Tolerability
Although the impact of non-adherence to medical therapy on clinical outcome has yet to be established, the issue is an important consideration in glaucoma management. As a chronic and progressive disease, glaucoma is a lifelong condition that will continually worsen without medical intervention. In most cases, POAG is asymptomatic until the disease has progressed enough to significantly damage the peripheral visual field; symptoms therefore present only at the advanced stage. Left untreated, loss of the visual field can extend from the peripheral to central vision.
However, lack of symptoms in the early stages of POAG means that many patients do not feel compelled to follow a therapeutic regimen. This is further compounded by medications that are associated with side effects, some of which can potentially reduce a patient's quality of life; if a patient feels no immediate therapeutic benefit from taking a drug but experiences irritating or debilitating side effects, the likelihood of that patient remaining compliant is low. The frequency of doses is also an issue, as a once-daily medication is generally better than a regimen that needs to be administered twice or thrice daily. 33, 57 In order to maintain long-term patient adherence in terms of both compliance and mediation persistence, tolerability should also be optimised to minimise ocular and systemic side effects. In order to convince patients to adhere to their medication, it is not sufficient only to preserve the visual field and prevent further damage; it is also necessary to offer a satisfactory level of quality of life with minimal adverse effects.
Furthermore, patient adherence needs to be continuously addressed by the physician.
Ocular Tolerability
Control of IOP is of course a very important variable to consider with respect to impact on patient outcome. For the most part, a lower IOP is generally better, but again it should be noted that the best practice is to individualise treatment. Nevertheless, the importance of ocular tolerability cannot be underestimated; poor tolerability negatively affects adherence to medication usage, and reduced compliance is the main reason for treatment failure. For glaucoma patients who require lifelong treatment and follow-up care to prevent disease progression and preserve vision, long-term patient compliance and persistence with medication is imperative.
One of the most important factors influencing compliance and persistence is the side effect profile, both local and systemic. 
